Medtronic DES study
This article was originally published in The Gray Sheet
Executive Summary
Firm announces the first patient implant was performed April 11 in its 1,548-patient, randomized trial to support the Endeavor ABT-578-eluting stent PMA. The study, named ENDEAVOR IV, will compare Endeavor head-to-head against Boston Scientific's Taxus paclitaxel-eluting stent by measuring target vessel failure at nine months as the primary endpoint and major adverse cardiac events at 30 days as a secondary endpoint (1"The Gray Sheet" Feb. 28, 2005, p. 19)...